Oxular Initiates OXEYE Phase 2 Clinical Trial
Oxular is proud to announce it has begun dosing in its OXEYE for diabetic macular edema (DME), a common retinal disorder with high treatment burden. In OXEYE, we are delivering Oxular’s suprachoroidal OXU-001, our sustained release microsphere formulation of dexamethasone, via Oxulumis®, our posterior suprachoroidal microcatheter delivery device, with an aim to provide a safe and …